Articles tagged "Sirolimus (SLR)"

2018 American Transplant Congress
Early Conversion to a CNI-Free Immunosuppression with SRL after Renal Tx – 10 yr Follow-Up Analysis of a Prospective Multicenter Trial
J. Andrassy,¹ M. Guba,¹ A. Habicht,² M. Fischereder,³ A. Pascher,⁴ K. Heller,⁵ B. Banas,⁶ O. Hakenberg,⁷ T. Vogel,⁸ T. Kauke.¹
¹Surgery, Ludwig-Maximilans-University, Munich, Germany; ²Transplant, Ludwig-Maximilans-University, Munich, Germany; ³Nephrology, MED IV, Ludwig-Maximilans-University, Munich, Germany; ⁴Surgery, Charitée University, Berlin, Germany; ⁵Medicine, University of Erlangen, Erlangen, Germany; ⁶Internal Medicine II, University of Regensburg, Regensburg, Germany; ⁷Urology, University of Rostock, Rostock, Germany; ⁸Surgery, University of Munster, Munster, Germany.
Introduction: A prospective multicenter trial comparing an early conversion to a CNI-free immunosuppression with SRL, MMF and steroids with a conventional CsA treatment following renal…
2017 American Transplant Congress
Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beynd Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750).
K.-W. Lee,¹ S.-H. Kim,² N.-J. Yi,¹ S.-K. Hong,¹ G. Yoon,¹ H. Kim,¹ D. Oh,¹ S.-S. Han,² S.-J. Park,² K.-S. Suh.¹
¹Department of Surgery, Seoul National University, Seoul, Republic of Korea; ²Center for Liver Cancer, National Cancer Center, Goyangsi, Republic of Korea
Background:It is unclear whether the reported benefit of mTORi in LT for HCC is from direct effect of mTOR inhibitors. We aimed to compare directly…
2017 American Transplant Congress
Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.
D. Fantus, Y. Ono, H. Dai, S. Yokota, O. Yoshida, A. Thomson.
Surgery, Thomas Starzl Transplantation Institute, Pittsburgh, PA
Background: Rapamycin (RAPA), is an immunosuppressive agent that inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and…
2017 American Transplant Congress
Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.
C. Larsen,¹ M. Alseiari,² S. Chandran,² F. Vincenti,² D. Wojciechowski.¹
¹Division of Nephrology, Massachusetts General Hospital, Boston, MA; ²Division of Nephrology, UCSF, San Francisco, CA
IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…
2017 American Transplant Congress
Alternations in Amplitude of Low Frequency Fluctuation in Renal Allograft Recipients That Received Tacrolimus or Sirolimus: An fMRI Study.
J. Wen,¹ X. Ni,¹ L. Wu,² G. Zheng,² L. Zhang,² J. Chen.¹
¹National Clinical Research Center of Kidney Diseases, Jinling Hospital, Medical School of Nanjing University, Nanjing, China; ²Department of Medical Imaging, Jinling Hospital, Medical School of Nanjing University, Nanjing, China
Objective The side-effects of resting tremor was common in renal transplant receipts receive tacrolimus. But the mechanism of this side-effect was unknown. This study want…
2017 American Transplant Congress
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.
S. Stead,¹ S. Kireta,² S. McInnes,³ P. Rose,¹ S. Jesudason,^1,2 S. Grey,⁴ D. Rojas-Canales,² R. Carroll,^1,2 N. Voelcker,⁴ P. Coates.^1,2
¹Medicine, University of Adelaide, Adelaide, Australia; ²Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ³ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide, Australia; ⁴Transplantation Immunology, Garven Institute of Medical Research, Sydney, Australia
Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…
2017 American Transplant Congress
Determinants of Successful Use of Sirolimus in Renal Transplantation.
M. Naik,¹ W. Gwinner,² W. Arns,³ E. Basic,¹⁰ K. Budde,¹ F. Diekmann,⁴ M. Fischereder,⁵ J. Goßmann,⁶ K. Heller,⁷ N. Heyne,⁸ J.-S. Jürgensen,¹ C. Morath,⁹ U. Riester.¹⁰
¹GSSG, Berlin, Germany; ²GSSG, Hannover, Germany; ³GSSG, Köln, Germany; ⁴GSSG, Barcelona, Spain; ⁵GSSG, München, Germany; ⁶GSSG, Frankfurt, Germany; ⁷GSSG, Erlangen, Germany; ⁸GSSG, Tübingen, Germany; ⁹GSSG, Heidelberg, Germany; ¹⁰GSSG - Pfizer, Berlin, Germany
Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…
2017 American Transplant Congress
Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?
K. Jayant,¹ I. Reccia,² J. Walton,¹ A. Sharma,³ A. Halawa.¹
¹Faculty of Health and Sciences, Institute of Learning and Teaching, University of Liverpool, Liverpool, United Kingdom; ²Department of Hepato-Pancreato-Biliary Surgery (HPB), Hammersmith Hospital, Imperial College, London, United Kingdom; ³Sheffield Teaching Hospitals, Sheffield Teaching Hospitals, Sheffield, United Kingdom
Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI…
2017 American Transplant Congress
mTOR Inhibitor and Low-Dose Tacrolimus in Pediatric Kidney Transplant (PKT): 9-Years Data of a Bi-Therapy Treatment.
R. Vilalta, E. Lara, A. Madrid, M. Muñoz, S. Chocron, G. Ariceta.
Pediatric Nephrology, Hosptal Vall d´Hebron, Barcelona, Spain
INTRODUCTIONNephrotoxicity , serious infectious, or malignancy risk , curtails tacrolimus use in PKT . However, based on potential antiviral and antitumoral actions of mTOR inhibitor…
2016 American Transplant Congress
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.
M. Burke,¹ L. Nahum,⁴ N. Isbel,¹ R. Carroll,³ H. Soyer,¹ R. Francis,¹ J. Bridge,¹ C. Staatz,² J. Wells.¹
¹Translational Research Institute, Brisbane, Australia; ²University of Queensland, Brisbane, Australia; ³Royal Adelaide Hospital, Adelaide, Australia; ⁴Ben Gurion University of the Negev, Beersheba, Israel.
BackgroundKidney transplant recipients (KTR) receiving sirolimus accrue fewer skin cancers than KTR receiving calcineurin inhibitor (CNI) based immunosuppression, potentially due to effects of sirolimus and…